MX2022015439A - Materiales y metodos para inhibir una infeccion virica, incluida una infeccion por coronavirus. - Google Patents

Materiales y metodos para inhibir una infeccion virica, incluida una infeccion por coronavirus.

Info

Publication number
MX2022015439A
MX2022015439A MX2022015439A MX2022015439A MX2022015439A MX 2022015439 A MX2022015439 A MX 2022015439A MX 2022015439 A MX2022015439 A MX 2022015439A MX 2022015439 A MX2022015439 A MX 2022015439A MX 2022015439 A MX2022015439 A MX 2022015439A
Authority
MX
Mexico
Prior art keywords
methods
infection
inhibiting
materials
coronavirus
Prior art date
Application number
MX2022015439A
Other languages
English (en)
Inventor
Eva A Berkes
Nicholas T Monsul
Frederick T Boehm
Yu-Hsien Liao
Original Assignee
Quorum Innovations Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quorum Innovations Llc filed Critical Quorum Innovations Llc
Publication of MX2022015439A publication Critical patent/MX2022015439A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Abstract

La presente invención proporciona composiciones y métodos para inhibir infecciones virales. Las modalidades preferidas de la invención proporcionan composiciones farmacéuticas y los métodos para usar las mismas, que comprenden una cepa de la bacteria Lactobacillus fermentum o extractos bioactivos de la misma.
MX2022015439A 2020-06-06 2021-06-07 Materiales y metodos para inhibir una infeccion virica, incluida una infeccion por coronavirus. MX2022015439A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063035733P 2020-06-06 2020-06-06
PCT/US2021/036104 WO2021248111A1 (en) 2020-06-06 2021-06-07 Materials and methods for inhibiting a viral infection, including a coronavirus infection

Publications (1)

Publication Number Publication Date
MX2022015439A true MX2022015439A (es) 2023-03-22

Family

ID=78831585

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015439A MX2022015439A (es) 2020-06-06 2021-06-07 Materiales y metodos para inhibir una infeccion virica, incluida una infeccion por coronavirus.

Country Status (11)

Country Link
US (2) US11826390B2 (es)
EP (1) EP4161558A1 (es)
JP (1) JP2023529152A (es)
KR (1) KR20230025853A (es)
CN (1) CN116133669A (es)
AU (1) AU2021286002A1 (es)
BR (1) BR112022024911A2 (es)
CA (1) CA3180737A1 (es)
IL (1) IL298401A (es)
MX (1) MX2022015439A (es)
WO (1) WO2021248111A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006163A (es) * 2019-11-26 2022-06-17 Quorum Innovations Llc Nuevas composiciones de barrera protectora y usos de las mismas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007040446A1 (en) 2005-10-06 2007-04-12 Probi Ab Use of lactobacillus for treatment of autoimmune diseases
WO2012141540A2 (ko) * 2011-04-13 2012-10-18 씨제이제일제당 (주) 바이러스 감염 억제 활성을 갖는 신규 분리한 락토바실러스 퍼멘텀 균주
BR112018001187B1 (pt) 2015-07-20 2022-02-15 Quorum Innovations, Llc Composição bacteriana, seus usos, método para melhorar condição de pele e método para desinfecção de uma superfície

Also Published As

Publication number Publication date
KR20230025853A (ko) 2023-02-23
BR112022024911A2 (pt) 2022-12-27
CA3180737A1 (en) 2021-12-09
JP2023529152A (ja) 2023-07-07
WO2021248111A1 (en) 2021-12-09
IL298401A (en) 2023-01-01
US11826390B2 (en) 2023-11-28
EP4161558A1 (en) 2023-04-12
WO2021248111A9 (en) 2022-12-22
US20240075083A1 (en) 2024-03-07
US20230136276A1 (en) 2023-05-04
AU2021286002A1 (en) 2023-01-19
CN116133669A (zh) 2023-05-16

Similar Documents

Publication Publication Date Title
CY1118006T1 (el) Χρηση γαλακτοβακιλλων για την αγωγη ιικων λοιμωξεων
MX2022011671A (es) Vacunas contra el coronavirus y metodos de uso.
WO2018158306A8 (en) BIFIDOBACTERIUM LONGUM MAY ADVANTAGEALLY MODULATE AN IMMUNE RESPONSE TO RESPIRATORY VIRUS INFECTION
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
HUP9802525A1 (hu) Hüvelyfertőzések kezelésére szolgáló, lactobacillus tartalmú gyógyászati készítmények
HK1043154A1 (en) A bacterial strain, processed plant extracts and probiotic compositions for human and veterinary use
WO2006083286A3 (en) Genetically engineered swine influenza virus and uses thereof
PH12018550110A1 (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
AU2016100865A4 (en) Multi-strain probiotic composition
MX2022015439A (es) Materiales y metodos para inhibir una infeccion virica, incluida una infeccion por coronavirus.
WO2023004415A3 (en) Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments
MX2022014561A (es) Inhibidores de mek para el tratamiento o prevencion de infecciones por coronavirus y/o tormenta de citocinas por covid-19.
WO2020091179A3 (ko) 프로바이오틱스를 유효 성분으로 포함하는 이차성 골다공증의 예방 또는 치료용 조성물
MX2022001973A (es) Formulaciones para la prevención o reducción de infecciones por c. difficile.
MX2022010877A (es) Cepas bacterianas y composiciones de las mismas para uso oral en el tratamiento de infecciones virales del aparato respiratorio.
WO2021004958A3 (en) Compositions comprising bacterial strains
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
WO2020091180A3 (ko) 프로바이오틱스를 유효 성분으로 포함하는 이차성 골다공증의 예방 또는 치료용 조성물
MX2020005373A (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis.
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
MX2022005251A (es) Conjugados de interleuquina 10 y sus usos.
EP4041222A4 (en) PROBIOTIC COMPOSITIONS ENHANCED WITH CANNABIDIOL AND THEIR USES FOR THE TREATMENT OF INFECTIONS
AU2018257122A1 (en) Pharmaceutical composition comprising attenuated streptococcus pneumoniae strains and use thereof
MX2019006086A (es) Uso de una composicion bacteriana para tratar infecciones en las patas de ungulados.
WO2019039781A3 (ko) 신규한 에로모나스 살모니시다 박테리오파지 ａｅｒ-ｓａｐ-2 및 이의 에로모나스 살모니시다 균 증식 억제 용도